It's a single-dose COVID-19 vaccine.
On Monday, May 3, The National Advisory Committee on Immunization (NACI) has recommended that Canadian provinces begin to administer the Johnson & Johnson COVID-19 vaccine to Canadians aged 30 or older.
The J&J vaccine is single-dose, which sets it apart from the Pfizer, Moderna, and AstraZeneca vaccines which require two doses.
The NACI's updated guidelines say that this vaccine may be a good option for Canadians 30 years old and older who "[do] not wish to wait for an mRNA vaccine and if the benefits outweigh the risk for the individual."
They also noted that it could be a more feasible option for people that would have a harder time getting two doses such as mobile populations and "certain hard to reach populations."
While the J&J vaccine is approved for use in Canada, the NACI continues to recommend the mRNA options for their "excellent protection."